Expression and clinical significance of CSAD in type I endometrial carcinoma

The current study aimed to identify the expression and clinical significance of cysteine sulfinate decarboxylase (CSAD) in type I endometrial carcinoma (EC). A total of 350 patients with endometrial lesions were involved in the study at Zhejiang University’s Women’s Hospital. Immunochemical staining was performed on samples of normal endometrium (NE), atypical endometrial hyperplasia (AEH), and type I EC. The study evaluated the association of CSAD staining with clinical characteristics and patient survival. CSAD expression in type I EC was elevated in comparison with NE, and increased expression correlates with International Federation of Gynecology and Obstetrics (FIGO) stages, Lymph vascular space invasion (LVSI), and Lymph node metastasis (LNM). High CSAD levels are associated with poor disease-free survival and overall survival. small interfering RNAs (siRNAs) can decrease CSAD expression, inhibit cancer cell proliferation, and affect B-cell lymphoma-2 (BCL-2) and BCL2-Associated X (BAX) protein expression. Our research indicates that higher levels of CSAD expression in type I EC was significantly associated with some clinical variables indicating poor prognosis and survival rate in patients with type I EC. patients and could promote cancer cell growth by affecting cell apoptosis rate.

Cysteine sulfinate; Decarboxylase; Type I endometrial carcinoma; Prognosis; Proliferation; Apoptosis

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024; 74: 12–49.

[2] Sheikh MA, Althouse AD, Freese KE, Soisson S, Edwards RP, Welburn S, et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncology. 2014; 10: 2561–2568.

[3] Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016; 387: 1094–1108.

[4] Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. Journal of the National Cancer Institute. 2018; 110: 354–361.

[5] Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME, Brinton LA. Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database. Cancer Epidemiology, Biomarkers & Prevention. 2015; 24: 261–267.

[6] Wang Y, Matye D, Nguyen N, Zhang Y, Li T. HNF4α regulates CSAD to couple hepatic taurine production to bile acid synthesis in mice. Gene Expression. 2018; 18: 187–196.

[7] Kerr TA, Matsumoto Y, Matsumoto H, Xie Y, Hirschberger LL, Stipanuk MH, et al. Cysteine sulfinic acid decarboxylase regulation: a role for farnesoid X receptor and small heterodimer partner in murine hepatic taurine metabolism. Hepatology Research. 2014; 44: E218–E228.

[8] Zhang D, Fan J, Liu H, Qiu G, Cui S. Testosterone enhances taurine synthesis by upregulating androgen receptor and cysteine sulfinic acid decarboxylase expressions in male mouse liver. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2023; 324: G295–G304.

[9] Kishimoto T, Kokura K, Nakadai T, Miyazawa Y, Wakamatsu T, Makino Y, et al. Overexpression of cysteine sulfinic acid decarboxylase stimulated by hepatocarcinogenesis results in autoantibody production in rats. Cancer Research. 1996; 56: 5230–5237.

[10] Zheng J, Zhang J, Zhou Y, Zhang D, Guo H, Li B, et al. Taurine alleviates experimental colitis by enhancing intestinal barrier function and inhibiting inflammatory response through TLR4/NF-κB signaling. Journal of Agricultural and Food Chemistry. 2024; 72: 12119–12129.

[11] Zhang D, Zheng J, Qiu G, Niu T, Gong Y, Cui S. CCl4 inhibits the expressions of hepatic taurine biosynthetic enzymes and taurine synthesis in the progression of mouse liver fibrosis. Human & Experimental Toxicology. 2022; 41: 9603271221135033.

[12] Rinaldi A, Cippà PE, Nemazanyy I, Anglicheau D, Pallet N. Taurine deficiency is a hallmark of injured kidney allografts. Transplantation. 2024; 108: e218–e228.

[13] Tochitani S. Taurine: A maternally derived nutrient linking mother and offspring. Metabolites. 2022; 12: 228.

[14] Huxtable RJ. Physiological actions of taurine. Physiological Reviews. 1992; 72: 101–163.

[15] Kim HJ, Kang IS, Kim C. Taurine chloramine inhibits leukocyte migration by suppressing actin polymerization and extracellular signal-regulated kinase. Advances in Experimental Medicine and Biology. 2022; 1370: 51–61.

[16] Stipanuk MH. Role of the liver in regulation of body cysteine and taurine levels: a brief review. Neurochemical Research. 2004; 29: 105–110.

[17] Laas E, Ballester M, Cortez A, Gonin J, Daraï E, Graesslin O. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer. Gynecologic Oncology. 2014; 133: 205–210.

[18] McCluggage WG, Bosse T, Gilks CB, Howitt BE, McAlpine JN, Nucci MR, et al. FIGO 2023 endometrial cancer staging: too much, too soon? International Journal of Gynecological Cancer. 2024; 34: 138–143.

[19] Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, et al. A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology. 2019; 145: 811–820.

[20] Cassier PA, Navaridas R, Bellina M, Rama N, Ducarouge B, Hernandez-Vargas H, et al. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature. 2023; 620: 409–416.

[21] Shawn LyBarger K, Miller HA, Frieboes HB. CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. Scientific Reports. 2022; 12: 19783.

[22] Perrone E, Capasso I, De Felice F, Giannarelli D, Dinoi G, Petrecca A, et al. Back to the future: the impact of oestrogen receptor profile in the era of molecular endometrial cancer classification. European Journal of Cancer. 2023; 186: 98–112.

[23] Jiang Y, Wang C, Zhou S. Artificial intelligence-based risk stratification, accurate diagnosis and treatment prediction in gynecologic oncology. Seminars in Cancer Biology. 2023; 96: 82–99.

[24] Hruda M, Sehnal B, Halaška MJ, Drozenová J, Robová H, Pichlík T, et al. New staging of endometrial carcinoma—FIGO 2023. Ceska Gynekologie. 2024; 89: 120–127.

[25] Ramon-Patino JL, Ruz-Caracuel I, Heredia-Soto V, Garcia de la Calle LE, Zagidullin B, Wang Y, et al. Prognosis stratification tools in early-stage endometrial cancer: could we improve their accuracy? Cancers. 2022; 14: 912.